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early and mid-term outcomes (mortality and prosthetic
valve reintervention) after mitral valve replacement with
15- to 17-mm mechanical prostheses.
Methods. Amulticenter, retrospective cohort study was
performed among patients who underwent mitral valve
replacement with a 15- to 17-mm mechanical prosthesis at
6 congenital cardiac centers: 5 in The Netherlands and 1
in the United States. Baseline, operative, and follow-up
data were evaluated.
Results. Mitral valve replacement was performed in 61
infants (15 mm, n [ 17 [28%]; 16 mm, n [ 18 [29%]; 17
mm, n [ 26 [43%]), of whom 27 (47%) were admitted to
the intensive care unit before surgery and 22 (39%)
required ventilator support. Median age at surgery was
5.9 months (interquartile range [IQR] 3.2-17.4), and me-
dian weight was 5.7 kg (IQR, 4.5-8.8). There were 13 in-
hospital deaths (21%) and 8 late deaths (17%, among 48Accepted for publication Apr 16, 2020.
Address correspondence to Dr IJsselhof, Department of Pediatric Cardiac
Surgery, University Medical Center Utrecht, Lundlaan 63584 EA, Utrecht,
The Netherlands; email: r.j.ijsselhof@umcutrecht.nl.
 2020 by The Society of Thoracic Surgeonshospital survivors). Major adverse events occurred in 34
(56%). Median follow-up was 4.0 years (IQR, 0.4-12.5)
First prosthetic valve replacement (n [ 27 [44%])
occurred at a median of 3.7 years (IQR, 1.9-6.8). Prosthetic
valve endocarditis was not reported, and there was no
mortality related to prosthesis replacement. Other rein-
terventions included permanent pacemaker implantation
(n [ 9 [15%]), subaortic stenosis resection (n [ 4 [7%]),
aortic valve repair (n [ 3 [5%], and aortic valve replace-
ment (n [ 6 [10%]).
Conclusions. Mitral valve replacement with 15- to
17-mm mechanical prostheses is an important alternative
to save critically ill neonates and infants in whom the
mitral valve cannot be repaired. Prosthesis replacement
for outgrowth can be carried out with low risk.
(Ann Thorac Surg 2020;-:---)
 2020 by The Society of Thoracic Surgeonsitral valve replacement (MVR) may be the onlyMsurgical option in some infants with severe
congenital MV stenosis or regurgitation, often after failed
repair.1 The prosthesis of choice is often a mechanical
prosthesis because these are available in smaller sizes
and are more durable than bioprosthetic counterparts,
particularly in young pediatric patients.2 Although me-
chanical prostheses > 17 mm have been the only avail-
able option for MVR in earlier eras, these prostheses were
often too large for infants and neonates, where the
normative values for lateral mitral annular diameter for
neonates (weight, 3 kg; height, 50 cm; body surface area
[BSA], 0.2 m2) ranges from 8 to 12 mm and at 1 year(weight, 7.5 kg; height, 71.5 cm; BSA, 0.4 m2) from 11 to
17 mm.3
Since 1995 mechanical prostheses have been available
in 16-mm and 17-mm sizes, and the 15-mm prosthesis has
been tested clinically and subsequently approved by the
U.S. food and drug administration in March 2018.4
Despite the use of 17-mm mechanical valves in centers
across the world, the small numbers in individual centers
has resulted in few reports of outcomes in the literature.
Understanding clinical outcome in patients who have
undergone MVR with 15- to 17-mm mechanical pros-
thesis can serve as a benchmark to determine utility and
benefits of bioprosthetic options, such as the stented
bovine jugular vein conduits, that have been introduced
as an alternative.5 The availability of 15-mm mechanical
prostheses for off-label use since 1998 allows us to report
a multiinstitutional experience with up to 20 years of
follow-up of 15- to 17-mm mechanical mitral prostheses0003-4975
https://doi.org/10.1016/j.athoracsur.2020.04.084
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related morbidity.Patients and Methods
Study Design
A multicenter, retrospective cohort study was performed
in patients who underwent MVR with 15- to 17-mm
mechanical prosthesis between January 1, 1998 and
December 31, 2018. These prostheses were implanted for
congenital mitral disease in 5 centers in the Netherlands
(University Medical Centers in Groningen, Leiden, Nij-
megen, Rotterdam, and Utrecht) and 1 in the United
States (Boston Children’s Hospital). Approval was ob-
tained from the institutional review board at each center,
with a waiver of informed consent, before collection of
clinical and echocardiographic data.
Data Collection
Collected data included basic demographic information,
descriptive anatomic diagnoses, associated noncardiac or
genetic anomalies, preoperative factors, echocardio-
graphic data, mortality, and other clinical adverse events
and reinterventions. Procedural details were obtained
from operative reports. Data on systemic anticoagulation
after mechanical valve implant were also collected.
Outcomes
The primary outcomes evaluated were mortality and
prosthesis replacement. Secondary outcomes were major
adverse events during index hospitalization; thrombo-
embolic events after valve implantation; resource utili-
zation as measured by postoperative days on ventilator,
postoperative intensive care unit (ICU) length of stay, and
hospital length of stay; and left ventricular function based
on follow-up echocardiography after discharge. Index
operation was defined as the first surgery where a 15- to
17-mm mechanical mitral prosthesis was inserted. Major
adverse events were defined according to The Society of
Thoracic Surgeons Congenital Heart Surgery Database.6,7
Postoperative days on the ventilator was defined as total
number of days on the ventilator after the index operation
and included all reintubation days. Postoperative ICU
length of stay was defined as total postoperative days in
the ICU, including days readmitted to the ICU during
hospitalization for the index operation.
Echocardiography
All echocardiographic studies were reviewed before sur-
gery, at discharge, and 0.5, 1, 2, 3, 5, and 10 years after
MVR when available. Measurements of the MV annulus
diameter in 2 planes, mitral valve gradient and degree of
valvular regurgitation and left ventricular function, were
performed by an experienced cardiologist applying the
recommendations of the American Society of Echocardi-
ography.8,9 Qualitative assessment of pulmonary artery
pressures (based on pulmonary regurgitation jet), right
ventricular pressures based on tricuspid regurgitation jet,
or septal position were also performed and pulmonaryhypertension was scored as none, mild to moderate, and
severe. Where echocardiographic images were not avail-
able for review, data from an echocardiographic report at
the appropriate time point were used.
Statistical Methods
Patient and procedural characteristics are summarized as
frequencies and percentages for categorical variables and
medians and interquartile ranges (IQRs) and/or ranges
for continuous variables. Cumulative incidence of death
after MVR was estimated by size of prosthesis using the
Kaplan-Meier method. Cumulative incidence of pros-
thesis replacement after MVR was estimated treating
death as a competing risk. The Wilcoxon signed-rank test
was used to evaluate change in valve size at the time of
prosthesis replacement. All analysis was performed in
SAS version 9.4 (SAS Institute Inc, Cary, NC).Results
Patients
Sixty-one patients were included in the analysis (Table 1),
with a median age at surgery of 5.9 months (IQR, 3.2-17.4;
range, 1 day to 5.3 years) and a median weight of 5.7 kg
(IQR, 4.5-8.8). Primary diagnosis was isolated congenital
MV stenosis/regurgitation in 29 (48%), atrioventricular
septal defect in 18 (30%), Shone and hypoplastic left heart
complex in 9 (15%), and other in 5 (8%). Twenty-seven
patients (47%) were treated in the ICU before surgery
and 22 (39%) were on mechanical ventilator support.
Thirty-four patients (56%) had previous attempts at
repair. Median time from repair to replacement was 26
days (IQR, 13-190). Thirteen patients (21%) underwent
MVR requiring a second bypass run at the index surgery
after failure of the initial mitral repair (n ¼ 11), iatrogenic
mitral regurgitation (prolapse of the anterior MV leaflet)
after an initial resection of the subaortic stenosis (n ¼ 1),
and severe mitral regurgitation and stenosis after an
initial Ross-Konno procedure (n ¼ 1).
Surgical Technique
Procedural details and outcomes are outlined in Table 2.
Transseptal access (50 [82%]) with excision of all valve
tissue (except the posterior leaflet in 9 patients 15%]) with
pledgets (if used) on the ventricular side of the annulus
was the preferred method. Orientation of the valve was
usually “antianatomic.” Annular implantation was
possible in 47 patients (77%) and supraannular in 14
(23%). Median pump time was 149 minutes (IQR, 110-
226), and median cross-clamp time was 99 minutes (IQR,
73-141).
Systemic Anticoagulation
Systemic anticoagulation included initial intravenous
heparin in all patients and was followed when clinically
feasible by vitamin K antagonist therapy (acenocoumarol,
half-life 8-11 hours; phenprocoumon, half-life 160 hours;
or warfarin, half-life 20-60 hours) in 36 (59%), aspirin in 4
Table 1. Patient and Procedural Characteristics (N ¼ 61)
Characteristic Value
Age at surgery, mo 5.9 (3.2-17.4)
Male sex 31 (51)
Weight at surgery, km 5.7 (4.5-8.8)
Preoperative status
In intensive care unit 27 (47)
On mechanical ventilator support 22 (39)
Previous surgery
MV repair 34 (56)
Repair–replacement interval, days 26 (13-190)
Pacemaker implantation 6 (10)
Diagnosis
Atrioventricular septal defect 18 (30)
Shone syndrome and hypoplastic left heart
complex
9 (15)
Isolated congenital MV stenosis and
regurgitation
29 (48)
Othera 5 (8)
Preoperative anatomy
Double-orifice MV 1 (2)
Parachute MV 7 (11)
Arcade type MV 1 (2)
Single papillary muscle 7 (11)
Absent or short chordae 20 (33)
Basally displaced papillary muscles 3 (5)
Genetics
Trisomy 21 3 (5)
Heterotaxy 3 (5)
aIncluded are parachute MV and ventricular septal defect, parachute MV
with hypoplastic left ventricle and double-outlet right ventricle, MV ste-
nosis with hypoplastic left ventricle and double-outlet right ventricle,
straddling of MV and Taussig Bing malformation, and Noonan syndrome
with hypertrophic cardiomyopathy.
Values are n (%) or median (interquartile range).
MV, mitral valve.
Table 2. Operative Outcome Data (N ¼ 61)
Variables Value
Transseptal access 50 (82)
Posterior leaflet remained intact 9 (15)
Type of valve
St Jude 44 (72)
Carbomedics 16 (26)
Sorin 1 (2)
Size of valve
15 mm 17 (28)
16 mm 18 (29)
17 mm 26 (43)
Valve position
Annular 47 (77)
Supraannular 14 (23)
Emergency procedure 6 (10)
Second bypass run 13 (21)
Perfusion time, min 149 (110-226)
Cross-clamp time, min 99 (73-141)
Concomitant procedurea 21 (34)
Condition at discharge
Atrioventricular block requiring pacemaker 9 (15)
Outcome
Major adverse eventsb 34 (56)
Prosthesis replacement 27 (44)
First to second replacement interval, y 3.7 (1.9-6.8)
Mortality
In-hospital 13 (21)
Postdischargec 8d
Days on ventilator 5 (1-9)
Intensive care unit length of stay, days 28 (12 - 56)
Hospital length of stay, days 41 (21-70)
Follow-up, y 4.0 (0.4-12.5)
aIncluded variables are Ross-Konno procedure (4), right atrioventricular
valve repair (3), resection of subaortic stenosis (2) with left ventricle
myectomy (1), aortic valve repair (2), resection of subaortic stenosis (1),
implantation of permanent pacemaker (1), coarctectomy with end-to-end
anastomosis (1), coarctation repair and arterial switch (1), closure of
ventricular septal defect (1) and atrial septal defect (fenestrated, 1), pul-
monary vein ostial resection (1), superior vena cava/ innominate vein
repair (1), and repair of left lower lobe vein ostium (1); bIncluded
variables are death before discharge (13), ventilator support >7 days
(17), pacemaker implantation (9), unplanned reoperation before
discharge (6), renal failure requiring dialysis (4), mediastinitis requiring
reoperation (4), postoperative extracorporeal membrane oxygenation
support (3), cardiac arrest requiring resuscitation (3), bleeding requiring
reoperation (3), and plication for paralysis or paresis of the diaphragm
(1); cAmong 48 hospital survivors; dMortality rate among hospital
survivors at 1, 2, and 5 years was 8.8%, 13.4% and 15.8%, respectively.
Values are n (%) or median (interquartile range).
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normalized ratio (INR) was 2.5 to 3.5.
Hospital Course
Sixty-three major adverse events occurred in 34 patients
(56%), including death prior to discharge (13, 21%),
ventilator support more than 7 days (17, 28%), permanent
pacemaker implantation (9, 15%), unplanned reoperation
before discharge (6, 10%), renal failure requiring dialysis
(4, 7%), mediastinitis requiring reoperation (4, 7%),
postoperative extracorporeal membrane oxygenation
support (3, 5%), bleeding requiring reoperation (3, 5%),
cardiac arrest requiring resuscitation (3, 5%), and plica-
tion for paralysis or paresis of the diaphragm (1, 2%).
Patients had 1 (18, 30%), 2 (11, 18%), 3 (1, 2%), 4 (1, 2%), 5
(2, 3%), or 6 (1, 2%) major adverse events. Major adverse
events are depicted in Table 3.
Unplanned reoperation before discharge included
repair of paravalvular leak (2, 3%), prosthetic valve
replacement for thrombosis (2, 3%), closure of VSD anddebanding of pulmonary artery (1, 2%), and implantation
of left ventricular assist device (1, 2%). Median post-
operative days on the ventilator and in the ICU were 5
(IQR, 1-9) and 28 (IQR, 12-56), respectively.
Mortality
In-hospital death occurred in 13 patients (21%). Death
was attributed to heart failure in all patients. Post-
discharge death occurred in 8 patients. Mortality rate
Table 3. Major Adverse Events
Patient
No.
Death or Heart
Transplantation
Before
Discharge
Postoperative
Extracorporeal
Membrane
Oxygenation
Support
Bleeding
Requiring
Reoperation
Plication for
Paralysis or
Paresis of the
Diaphragm
Mediastinitis
Requiring
Reoperation
Ventilator
Support >
7 Days
Cardiac
Arrest
Requiring
Resuscitation
Renal
Failure
Requiring
Dialysis
Unplanned
Cardiac
Reoperation
Before
Discharge Pacemaker
1 x x
2 x
3 x
4 x
5 x
6 x x x
7 x
8 x
9 x x
10 x
11 x x
12 x x
13 x x
14 x x
15 x
16 x x
17 x x
18 x
19 x x x x x x
20 x x x x
21 x x
22 x
23 x
24 x
25 x
26 x x
27 x x x x x
28 x x x x x
29 x
30 x
31 x
32 x
33 x
34 x x
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Figure 2. Cumulative incidence of prosthetic valve replacement
based on size of prosthesis, treating death as a competing risk.
Prosthesis size of 15 mm is depicted in blue, 16 mm in red, and 17 mm
in green. (MVR, mitral valve replacement.)
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13.4%, and 15.8%, respectively. Death was attributed to
heart failure in 2 patients and to a noncardiac cause in 6
patients (pneumonia, 2; respiratory insufficiency, 2; and
intracerebral bleeding, 2). Figure 1 shows the cumulative
incidence of death after MVR by size of prosthesis (log-
rank test P ¼ .079). Time to death did not differ signifi-
cantly between patients with annular or supraannular
valves (P ¼ .36).
Prosthetic Valve Replacement
Prosthesis replacement was required in 27 patients (44%).
The main indication for prosthesis replacement was
patient–prosthesis mismatch in 17 (28%). Other in-
dications were prosthesis thrombosis in 5 (8%) and (para)
valvular leak in 3 (5%), leaflet immobility and failure of
prosthesis in 1 (2%), and pannus in 1 (2%). Among the 27
patients with replacement, median time to prosthetic
valve replacement was 3.7 years (IQR, 1.9-6.8). Estimated
freedom from prosthesis replacement at 1, 2, and 5 years
was 90%, 85%, and 60%, respectively. Most prostheses
were replaced by mechanical valves (24, 39%). Other
valves used for prosthesis replacement were porcine (2,
3%) and pericardial valves (1, 2%). Sizes used were 15 mm
(1, 4%), 16 mm (3, 12%), 17 mm (1, 4%), 19 mm (8, 31%), 21
mm (5, 19%), 23 mm (8, 31%), and 25 mm (1, 4%). Larger
prostheses could be used for prosthesis replacement in all
cases except for 1 (downsized 1-mm because of prosthesis
thrombosis after 1.5 years) and 3 (same size because of
prosthesis thrombosis in 2 after 1 and 1.5 months and
because of prosthesis dysfunction in 1 after 1.5 months).
Figure 2 represents the cumulative incidence of pros-
thetic valve replacement based on size of prosthesis,
treating death as a competing risk. Risk of prosthesis
replacement is greater for subjects with 15-mm valves
when compared with those with larger valves (Fine and
Gray model, P ¼ .019). Time to prosthetic valve replace-
ment did not differ significantly between patients with
annular and supraannular valves (P ¼ .70). There was noFigure 1. Cumulative incidence of death after mitral valve
replacement (MVR) by size of prosthesis. Prosthesis size of 15 mm is
depicted in blue, 16 mm in red, and 17 mm in green.significant difference in BSA across valve sizes (P ¼ .22)
(Figure 3). In patients with initial MVR at the annular and
supraannular level, prosthesis could be upsized by a
median of 4 mm (signed-rank test P < .001) and 5 mm
(signed-rank test P ¼ .031), respectively.
Other indications for reoperation were resection of
subaortic stenosis (4 [7%]), aortic valve repair (3 [5%]),
and aortic valve replacement (6 [10%]). One patient un-
derwent aortic valve repair and replacement during
separate procedures.
Thromboembolic/Bleeding Events
Six patients (10%) had prosthesis thrombosis, including 1
patient with a thrombosis after prosthesis replacement
with a 23-mm St Jude Medical prosthesis, 3 of whom had
persisting neurologic deficit. One of these thromboem-
bolic events was related to a malfunctioning prosthesis
(reduced cusp mobility of 15-mm prosthesis 1 week after
implantation). Prosthesis inspection during replacement
revealed absent mobility of the posterior leaflet and small
thrombi on the leaflet and in the hinge mechanism. The
prosthesis was removed and a new 15-mm prosthesis
implanted (Table 4, patient 1). Another prosthesis
thrombosis was related to subtherapeutic INR level
(infection). In the other patients the cause of the pros-
thesis thrombosis remained unclear. There was a single
bleeding event reported (1, 1.6%), related to an elevated
INR level (inadvertent intake of higher than prescribed
medication dose).
Follow-up
Median follow-up time was 4.0 years (IQR, 0.4-12.5). Eight
patients (13%) experienced a thromboembolic/bleeding
event (Table 4) (7 [11%] after index surgery, 1 [2%] after
prosthesis replacement with a 23-mm mechanical pros-
thesis). Among 25 patients with echocardiographic data at
10 years, left ventricular function was normal in 17 (68%),
mildly depressed in 7 (28%), and moderately depressed in
Figure 3. Body surface area (BSA) across valve size. There was no
significant difference in BSA across valve size (P¼ .22). (MVR, mitral
valve replacement.)
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diographic measurements of pulmonary/right ventricular
pressures there was no evidence of pulmonary/right
ventricular hypertension in 16 patients (73%), mild to
moderate in 5 (23%), and severe in 1 (4%).Comment
This multicenter, retrospective review reports a 20-year
experience with mechanical MVR using small prosthesis
(15-17 mm) in children, with particular emphasis on
mortality and valve-related morbidity. The in-hospital
mortality (21%) was high but comparable with studies
with similarly sized mechanical prostheses (18%-19%)10,11
and was higher compared with studies where larger-
diameter mechanical prostheses were used (6%-11%),12-14
albeit in older and larger patients. High mortality is likely
related to the poor preoperative clinical condition of theTable 4. Thromboembolic/Bleeding Events
Patient No.
Thromboembolic
Events
Time Since Valve
Replacement (mo)
1 Prosthesis thrombosis 0.9
2 Prosthesis thrombosis 3.9
3 Prosthesis thrombosis 21.9
4 Prosthesis thrombosisa 88.7
5 Stroke 6.0
6 Prosthesis thrombosis 6.6
7 Prosthesis thrombosis 17.3
Patient No. Bleeding Events
Time Since Valve
Replacement (y)
1 Subdural hemorrhage 2.8
a23mm mechanical prosthesis; bPerioperative stroke (Ross-Konno proced
hospitalization.
INR, international normalized ratio.patients in our cohort, with 39% ventilated preoperatively
for cardiorespiratory failure.
Mortality rates (both in-hospital [21%] and post-
discharge [17%]) in our cohort were higher compared
with the rates reported by Pluchinotta and colleagues15 of
12% (early) and 8% (late) in a recent multicenter study
among 59 slightly older and larger patients who under-
went MVR with a stented bovine jugular vein conduit.
High in-hospital mortality rates in our cohort may be
explained by worse preoperative risk status and the
greater number of concomitant procedures (21 [34%]) in
our cohort. Most patients who suffered an early cardiac
death were admitted to the ICU and on ventilator support
before surgery, indicative of compromised hemody-
namics. The elevated postdischarge mortality rate in our
cohort may be explained by a longer duration of follow-
up in our cohort compared with the Pluchinotta’s cohort
(median of 4.0 years vs mean of 23 months). Furthermore
Pluchinotta and colleagues15 reported the development of
structural bovine jugular vein conduit deterioration in a
significant number (35%) of patients, requiring prosthesis
replacement at median of 22 months after implantation.
Of note the rate of prosthesis replacement in our cohort,
although similar (44%), occurred later with a median time
to prosthesis replacement of 44 months.
A trend of better survival in patients with 15-mm valves
compared with those with 16- and 17-mm valves was
seen, although it did not achieve statistical significance
(P ¼ .079). Of note we found no significant difference in
BSA across valve size (Figure 3), indicating valve over-
sizing in patients where 16- and 17-mm valves were used.
We speculate that using a 16- or 17-mm valve carries the
risks associated with oversizing, that is, left ventricular
outflow tract obstruction or compression of the circumflex
coronary to name a few, which may eventually result in
low cardiac output syndrome and death. However
missing data on preoperative mitral valve diameters did
not permit an analysis to confirm or reject this hypothesis.
The finding of higher incidence of mortality with 16- andAnticoagulation
Persisting (Neurologic)
Deficit
Fenprocoumon (INR, 3.1-4.5) No
Fraxiparine Yes
Acenocoumarol (INR, 1.8-3.3) Yes
Acenocoumarol No
Otherb Yes
Fraxiparine and Ascal Yes
Warfarin No
Anticoagulation
Persisting (Neurologic)
Deficit
Fenprocoumon (INR, 7) Yes
ure with postoperative mechanical circulatory support) during separate
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hesitate to make any inferences.
Patients in our series remained free from prosthesis
replacement for a median of 3.7 years, with patient–
prosthesis mismatch being the most common indication
for prosthesis replacement. Prosthetic valve endocarditis
was not reported, and there was no mortality related to
prosthesis replacement. A larger prosthesis could be used
in most patients, with a median increase in prosthesis size
by 4 mm during prosthesis replacement. This finding is
consistent with other studies that have demonstrated
mitral annular growth despite the restriction induced by a
prosthetic ring because complete removal of the initial
prosthesis allows the native annulus to expand.16-18
One of the concerns associated with prosthetic valve
replacement in children with a small mitral annulus is
that the annulus can rarely be surgically enlarged due to
proximity to vital structures, and annular implantation of
larger prosthesis has been associated with heart block,
compression of the circumflex coronary, or left ventricu-
lar outflow tract obstruction.10,19 Supraannular prosthesis
implantation remains an alternative option in patients
with small MV annulus sizes, with poor20 to excellent21
results reported in small series of patients. In our cohort
heart block requiring pacemaker (9 [15%]), subaortic
stenosis resection (4 [7%]), and circumflex artery
compression (1 [1.6%]) did occur, despite the fact that
most prostheses were implanted at the annular level. We
used the supraannular technique in 14 patients (23%) so
that an adequately sized prosthesis could be implanted
while avoiding the complications of an oversized pros-
thesis in the true annulus. Both time to death and time to
prosthesis replacement did not significantly differ be-
tween patients with prosthesis implanted at the annular
or supraannular level.
The choice of prosthesis (ie, a small mechanical pros-
thesis vs a bioprosthesis such as a stented bovine jugular
vein conduit) is best determined by the individual sur-
geon and cardiologist. In the short term the morbidity
and mortality risks for 15- to 17-mm mechanical pros-
theses are comparable with that of a bovine jugular vein
contegra conduit.15 The incidence of thromboembolic
complications and difficulty of managing anticoagulation
in a small child are clearly important disadvantages with
mechanical valves when compared with bioprosthetic
valves such as the stented bovine jugular vein conduit,
especially in countries with limited INR monitoring op-
tions where easy access and low costs may favor the
mechanical prosthesis. Furthermore endocarditis has
been reported after transcatheter bovine jugular vein
contegra conduit implantation15,22 in both mitral and
pulmonary positions, whereas in our cohort infectious
endocarditis was not documented in any of the patients.
Long-term outcome of the stented bovine jugular vein
conduit are needed and can contribute to clinical
decision-making on choice of prosthesis.
Study Limitations
This is a retrospective cohort study with inherent limita-
tions of missing data. Echocardiography protocolsdiffered among the participating centers, resulting in
missing data for some echocardiographic variables.
However to avoid interobserver variability the studies
when available were reviewed by experienced cardiolo-
gists from the 2 coordinating centers. The surgery reports
did not always document details on whether pledgets
were used at the time of the implant. We therefore were
unable to analyze for differences in outcomes when
pledgets were used versus not used. Furthermore there
was no bioprosthetic valve comparator group in this
study.
Conclusions
Small-sized mechanical prosthetic valves may be an
important alternative in critically ill neonates and infants
who require MVR. Inevitable prosthesis replacement for
outgrowth was required at a median of 3.7 years and
could be carried out with low risk. Anticoagulation and
associated morbidity remains a challenge.
This study had no external sources of funding and was supported
by internal departmental funding at University Medical Center,
Utrecht, the Netherlands, and Boston Children's Hospital, Bos-
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